A Comparison of the Postoperative Outcomes of Laparoscopic Sacrocolpopexy and Transvaginal Surgery Using ORIHIME(®) Mesh with Wide Arms for Pelvic Organ Prolapse

腹腔镜骶骨阴道固定术与使用ORIHIME®宽臂网片经阴道手术治疗盆腔器官脱垂的术后结果比较

阅读:1

Abstract

OBJECTIVES: Both transvaginal mesh surgery with wide arms (TVMWA) and laparoscopic sacrocolpopexy (LSC) are effective surgical treatments for pelvic organ prolapse (POP) with reportedly low recurrence rates. In the present study, we compared the postoperative outcomes of TVMWA and LSC. MATERIALS AND METHODS: We retrospectively evaluated 142 patients with POP who underwent LSC or TVMWA at our hospital. We measured the changes in lower urinary tract symptoms before and after surgery using the International Prostate Symptom Score (IPSS) plus Quality of Life (QOL) score, Overactive Bladder Symptom Score (OABSS), International Consultation on Incontinence Questionnaire Short-Form (ICIQ-SF), postvoiding residual urine volume (PVR), and 60-min pad weight testing. RESULTS: The median blood loss was much lower in the LSC group than in the TVMWA group. However, the median surgical duration was significantly longer in the LSC group than in the TVMWA group (both P < 0.0001). The PVR, IPSS plus QOL scores, OABSS, and ICIQ-SF scores all decreased significantly after surgery in both the groups. There were no significant changes between the pre- and postoperative 60-min pad weights in either group. There were no significant differences in the rate of stress urinary incontinence, mesh exposure, or prolapse recurrence after surgery between the two groups. ICIQ-SF scores were significantly more improved in the TVMWA group compared to the LSC group. CONCLUSION: We conclude that both TVMWA and LSC are effective surgical methods of ameliorating POP. However, considering the burden such as longer operative time on the patient treated with LSC, we recommend more frequent employment of TVMWA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。